New Research Released on Emerald Health Pharmaceuticals (CLOSELY-HELD)

Posted by Karen Goldfarb

November 30, 2021 at 6:22 PM

An Executive Informational Overview (EIO) is now available on Emerald Health Pharmaceuticals Inc., a closely-held clinical-stage biotechnology company developing novel proprietary therapeutic molecules to treat various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with no current cure. The 74-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Emerald Health Pharmaceuticals Initiation Report

Read More

Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, fibrotic, multiple sclerosis, Huntingtons Disease, cannabigerol, SSc, inflammatory, systemic sclerosis, MS, Parkinsons Disease, cannabinoids, cannabidiol

November 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

November 17, 2021 at 9:28 AM

Crystal Research Associates has issued a 13-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic